HIV-1 dynamics and coreceptor usage in Maraviroc-treated patients with ongoing replication.

P Recordon-Pinson (1, 2) , P Bellecave (2, 1) , S Raymond (3, 4) , a G Marcelin (5) , C Soulie (6, 5) , D Descamps (7, 8) , V Calvez (9, 5, 6) , P R Harrigan (10) , H Fleury (2, 1) , Jacques Izopet (3, 4) , B Masquelier (2, 1)

1 MFP - Microbiologie Fondamentale et Pathogénicité
2 Service de virologie et d'immunologie biologique
3 CPTP - Centre de Physiopathologie Toulouse Purpan
4 Laboratoire Virologie [CHU Toulouse]
5 CHU Pitié-Salpêtrière [AP-HP]
6 Epidémiologie, stratégies thérapeutiques et virologie cliniques dans l'infection à VIH
7 CELIA - Centre d'Etudes Lasers Intenses et Applications
8 Service de Virologie [CHU Bichat]
9 NUMED - Numerical Medicine
10 British Columbia Centre for Excellence in HIV/AIDS [Vancouver]

There is evidence that HIV-1 evolution under maraviroc (MVC) pressure can lead to the selection of either X4-tropic variants and/or R5-tropic, MVC-resistant isolates. However, the viral dynamics of HIV-1 variants in patients with virological failure (VF) on MVC-containing regimens remain poorly studied. Here, we investigated the V3 loop evolution of HIV-1 on MVC in relation to coreceptor usage and the nature of HIV-1 quasispecies before MVC therapy using bulk population sequences and ultradeep sequencing. The majority of patients had no detectable minority X4 variant at baseline. The evolution of tropism was followed up until VF and showed three possibilities for viral evolution in these patients: emergence of preexisting X4 variants, de novo selection of R5 variants presenting V3 loop mutations, or replication of R5 variants without selection of known mutations.

Domaines: Microbiologie et Parasitologie

P Recordon-Pinson, P Bellecave, S Raymond, a G Marcelin, C Soulie, et al.. HIV-1 dynamics and coreceptor usage in Maraviroc-treated patients with ongoing replication.. Antimicrobial Agents and Chemotherapy, 2013, 57 (2), pp.930-935. ⟨10.1128/AAC.02159-12⟩. ⟨hal-01101119⟩